AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04401566 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: The Control group will have a paper about exercises recommended in pelvic pain for 30 minutes. A physiotherapist will teach and show the exercises for pelvic pain. The home exercise for pelvic pain contains diaphragm breating, pelvic floor muscle stretching and releasing.
Study NCT03738332 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Low-Level Laser
Description: Low-level laser therapy
Study NCT04041609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYR-210
Description: A single administration of LYR-210 depot
Study NCT04041609 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Sham comparator
Study NCT01825109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine & Breastfeeding
Description: Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
Study NCT01825109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine & Breastfeeding
Description: Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
Study NCT01825109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine & Breastfeeding
Description: Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
Study NCT01825109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine & Breastfeeding
Description: Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
Study NCT02983448 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous vagus nerve stimulation
Description: All patients will receive both active and sham transcutaneous vagus nerve stimulation, with the order being randomized
Study NCT02983448 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcutaneous vagus nerve stimulation
Description: All patients will receive both active and sham transcutaneous vagus nerve stimulation, with the order being randomized
Study NCT01133821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IPSRT plus placebo (IPSRT-PLA)
Description: Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)
Study NCT01133821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPSRT plus quetiapine
Description: Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)
Study NCT03977584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab
Description: Crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
Study NCT03977584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
Study NCT03977584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [^18F]GTP1
Description: IV \[\^18F\]GTP1 will be administered up to three times. The first primary \[\^18F\]GTP1 tau PET scan will occur during any visit in the main protocol NCT01998841 (GN28352) from Week 130 to Week 224 and the second \[\^18F\]GTP1 tau PET scan from Week 248 to Week 260. The third and optional \[\^18F\]GTP1 tau PET scan will supplement the two primary scans.
Study NCT01274338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV and SC
Study NCT02639273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: Active Drug
Study NCT02639273 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Dose Placebo
Study NCT01534598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FdCyd + THU
Description: Intravenous FdCyd with THU has been evaluated in a Phase I clinical trial with some preliminary evidence of activity. This trial will investigate oral administration of the drugs, which was shown to be feasible in an expansion cohort of the previous trial.
Study NCT03646045 — intervention group
Intervention type: OTHER
Intervention: Transpyloric feeding
Description: Preterm infant feeding using transpyloric feeding tube (nasoduodenal tube)
Study NCT01167712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01167712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01167712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Correlative studies
Study NCT01167712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01167712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT00401518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Randomized ACADIA® Facet Replacement System
Description: Randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
Study NCT00401518 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Randomized Instrumented posterolateral fusion (PLF)
Description: Randomized control treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis
Study NCT02721498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Airway clearance session using the Active Cycle of Breathing Techniques (ACBT)
Description: An airway clearance technique incorporating thoracic expansion exercises, breathing control (normal diaphragmatic breathing) and the forced expiration technique (or huffing)
Study NCT02721498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rest period
Description: A 30-60 minute of resting
Study NCT02417857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Cholecystectomy (Single Incision)
Description: We performed Single Incision Laparoscopic Cholecystectomy (SILC) operation to the group-1
Study NCT02417857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Cholecystectomy (Conventional)
Description: We performed Conventional Laparoscopic Cholecystectomy (CLC) to group-2
Study NCT02590237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu KingVision Video Laryngoscope aBlade
Description: At time of tracheal intubation, the subject will be intubated using the Ambu KingVision Video Laryngoscope with a size 1 aBlade. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
Study NCT02590237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miller Direct Laryngoscopy
Description: At time of tracheal intubation, the subject will be intubated using a Miller blade laryngoscope. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
Study NCT02714010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI
Description: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
Study NCT02714010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGFR-TKI
Description: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
Study NCT02714010 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole brain radiotherapy
Description: 30Gy/10F
Study NCT04568798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sana Sham Device
Description: Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
Study NCT04745169 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 8 week home-based exercise program
Description: Participants will be asked to complete an 8-week home-based exercise program according to guidelines from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation. At study baseline, participants will receive exercise equipment and an individualized exercise prescription from an exercise physiologist followed by 8 weekly phone calls from an exercise physiologist. Participant safety will be monitored.
Study NCT03073941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persona total knee system
Description: 314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
Study NCT03073941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nexgen total knee system
Description: 314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
Study NCT04568798 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sana Sham Device
Description: Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
Study NCT01738529 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CLE ileocolonoscopy
Description: The patients enrolled including the control group, will be investigated respectively, by conventional colonoscopy and CLE in both the terminal ileum as colon. The degree and extent of Crohn's disease are assessed by conventional ileocolonoscopy (SI), CLE (selected parameters) and histology biopsies. Then, the correlation between histology (gold standard), SI and CLE is calculated. An intra-and inter-observer study follows on CLE parameters, where 3 observers are blinded with respect to each other. The pathologist is blinded to conventional and CLE parameters. CLE results are stratified in order to identify which of the recorded CLE parameters that correlate best with the two other methods.
Study NCT01738529 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CLE ileocolonoscopy
Description: The patients enrolled including the control group, will be investigated respectively, by conventional colonoscopy and CLE in both the terminal ileum as colon. The degree and extent of Crohn's disease are assessed by conventional ileocolonoscopy (SI), CLE (selected parameters) and histology biopsies. Then, the correlation between histology (gold standard), SI and CLE is calculated. An intra-and inter-observer study follows on CLE parameters, where 3 observers are blinded with respect to each other. The pathologist is blinded to conventional and CLE parameters. CLE results are stratified in order to identify which of the recorded CLE parameters that correlate best with the two other methods.
Study NCT01827592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 10 mg
Description: Elobixibat 10 mg/day
Study NCT01827592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 5 mg
Description: Elobixibat 5 mg/day
Study NCT01827592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04036591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Acute Bronchiolitis Severity Scale (ABSS)
Description: All infants will be assessed using the Acute Bronchiolitis Severity Scale (ABSS) before and after being treated by experienced physiotherapists using the prolonged slow expiration technique and provoqued cough. Before the application of these techniques a retrograde rhinopharyngeal unclogging will be performed in order to clean the nasopharynx.
Study NCT04639362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib, venetoclax, obinutuzumab
Description: Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.
Study NCT04639362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib, venetoclax
Description: Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
Study NCT03520712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Valoctocogene Roxaparvovec
Description: Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
Study NCT01034228 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ORS + Isoleucine
Description: ORS with Isolelucine for treatment of diarrhoeal in children
Study NCT01034228 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ORS without Isoleucine
Description: ORS without Isoleucine for the treatment of diarrhoea in children
Study NCT04296578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Standard of Care (SOC) abiraterone (Zytiga) as per package insert. The recommended dose of ZYTIGA is 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily.
Study NCT04296578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Selenite
Description: 11 mg tablets
Study NCT04296578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: SOC prednisone 5 mg PO twice daily
Study NCT06784739 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Venous blood sampling
Study NCT04468724 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MAKASI
Description: The Makasi intervention consists in a unique Empowerment interview, based on motivational interviewing techniques. Is is made of three components:~* Listening and building trust~* Active referral to structures that answers sanitary and social needs~* Sexual Health Prevention~Materials used are: referral letters, bilingual health guides, adapted maps of the the neighborhoods with useful addresses.~The Makasi intervention is proposed and delivered in an outreach setting: health mediators propose information on general health and rapid HIV and HCV testing. They screen the people attending and propose Makasi to eligible persons.
Study NCT04468724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAKASI
Description: The Makasi intervention consists in a unique Empowerment interview, based on motivational interviewing techniques. Is is made of three components:~* Listening and building trust~* Active referral to structures that answers sanitary and social needs~* Sexual Health Prevention~Materials used are: referral letters, bilingual health guides, adapted maps of the the neighborhoods with useful addresses.~The Makasi intervention is proposed and delivered in an outreach setting: health mediators propose information on general health and rapid HIV and HCV testing. They screen the people attending and propose Makasi to eligible persons.
Study NCT03448523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Right To Play's Positive Child and Youth Development program
Description: 1. Right To Play's Red Ball Child Play manual provided for 60 hours per annum for two years~2. Training of junior leaders~3. Related play-based activities such as sports days~4. Quarterly awareness sessions with community groups and parents~5. Summer camps for children~6. training of teachers on Right To Play's foundational resources, positive disciplining, and gender and child protection
Study NCT00684164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan
Description: 20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days
Study NCT00684164 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: D5
Description: Volume loading dose of D5 followed by an infusion of D5 over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
Study NCT06784739 — intervention group
Intervention type: OTHER
Intervention: Mucosal sampling
Description: Saliva and nasal secretions
Study NCT06784739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PCR-test
Description: RT qPCR test to determine infection with SARS-CoV-2, Influenza A/B and/or RSV A/B.
Study NCT06785077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: buccal cells
Description: custom myeloid gene panel (Myelo-Panel) to identify germline mutations predisposing to cancer development (Thermo Fisher Scientific)
Study NCT06785077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow cells
Description: Bone marrow cells (optional, for comparison, only in a limited number of patients):~* morphological analysis~* immunophenotype~* cytogenetics/FISH~* analysis of CHIP by custom gene panel and high sensitivity NGS
Study NCT06785077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood cells
Description: analysis of CHIP by custom gene panel and high sensitivity NGS
Study NCT06785077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow biopsy
Description: Bone marrow biopsy (optional, for comparison, only in a limited number of patients):~* histology~* immunohistochemistry
Study NCT03206827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 70% animal, 30% plant proteins in diet
Description: Diet contains 70% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 30% from plant sources (bread and cereals).
Study NCT03206827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50% animal, 50% plant proteins in diet
Description: Diet contains 50% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 50% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
Study NCT03206827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30% animal, 70% plant proteins in diet
Description: Diet contains 30% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 70% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
Study NCT01039779 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise will be taught every week over the 6-month intervention period at a subject's residence by instructors.
Study NCT01353391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
Study NCT01353391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
Study NCT04823390 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam-Fentanyl combination
Description: Sedation is given to patients undergoing cataract surgery under local anesthesia
Study NCT03491787 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound guidance
Description: The ultrasound guidance was used to obtain intraosseous access
Study NCT03446118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI to detect inflammation and fibrosis in subjects with EoE
Description: MRI will be performed on a 1.5T magnet. Patients will be scanned in an oblique prone position similar to how esophageal distention is assessed at barium fluoroscopy